VCs find common ground in post-SVB survey

A week after the collapse of Silicon Valley Bank, VCs have much to say about why that disaster unfolded, what lessons are being learned and what it means for biotech in the near term. And while they differ on some issues, they are fairly unified on three: the fact VCs did what they had to do that fateful day; returning their business to SVB’s successor will depend on who ends up owning it; and the need for better regulatory controls on banks of SVB’s size. 

Those are the results of a BioCentury survey that captured the opinions of 68 VCs in the U.S., Europe and Asia, conducted March 17-20. The survey was anonymous, but gave plenty of flavor via write-in comments for how VCs are digesting the fallout...